# DESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer

Source: https://onco.cc/key-papers/paper-destiny-lung01-nejm-2022/  
OnCo record `paper-destiny-lung01-nejm-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Trastuzumab deruxtecan shrank tumours in more than half of patients with previously treated HER2-mutant lung cancer, a driver with no approved therapy until this study, though lung inflammation was a serious side effect.

## Summary

Phase 2 study of 91 patients with previously treated HER2-mutant metastatic non-small-cell lung cancer treated with trastuzumab deruxtecan 6.4 mg/kg.

Objective response was 55 percent with median duration of response 9.3 months, median progression-free survival 8.2 months and median overall survival 17.8 months; drug-related interstitial lung disease occurred in 26 percent with two deaths.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: New England Journal of Medicine
- Year: 2022
- DOI: 10.1056/NEJMoa2112431
- Authors: Li BT, Smit EF, Goto Y, et al.
- Findings: Objective response 55 percent; median duration of response 9.3 months.; Median overall survival 17.8 months; interstitial lung disease 26 percent.
- What it means: HER2 mutations, present in about 3 percent of lung adenocarcinomas, became actionable; trastuzumab deruxtecan received the first approval for a HER2-mutant lung cancer, at the lower 5.4 mg/kg dose validated in DESTINY-Lung02.
- Caveats: High rate of interstitial lung disease at 6.4 mg/kg.; Single-arm study.

## Sources

- N Engl J Med 2022: https://doi.org/10.1056/NEJMoa2112431
- PubMed: https://pubmed.ncbi.nlm.nih.gov/34534430/

## Connected records

- cancers: [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- trials: [DESTINY-Lung01](https://onco.cc/trials/destiny-lung01/)
- journals: [New England Journal of Medicine](https://onco.cc/journals/nejm/)

---
JSON: https://onco.cc/api/v1/entities/paper-destiny-lung01-nejm-2022.json